2型糖尿病患者达格列净血药浓度与UGT1A9基因多态性相关性研究  

Correlation of Dapagliflozin Plasma Concentration with UGT1A9 Gene Polymorphisms in Patients with Type 2 Diabetes Mellitus

作　　者：刘彦儒 龚婧如 蒋喆 陆惠平 LIU Yanru;GONG Jingru;JIANG Zhe;LU Huiping(Shanghai Pudong Hospital,Shanghai,China 201399)

机构地区：[1]上海市浦东医院,上海201399

出　　处：《中国药业》2024年第24期66-69,共4页China Pharmaceuticals

基　　金：上海市浦东新区卫生系统学科建设项目[PWZy2020-14];复旦大学附属浦东医院重点专科/专病诊治中心项目[Tszk2020-05]。

摘　　要：目的考察2型糖尿病患者达格列净血药浓度与尿苷二磷酸葡萄糖醛酸转移酶(UGT)1A9基因多态性的相关性。方法选取医院2021年3月至6月接受达格列净治疗的2型糖尿病患者30例,用药至少3 d后,采用液相色谱串联质谱法测定达格列净稳态血药浓度,采用测序法测定UGT1A9基因型,比较不同基因型患者达格列净血药浓度的差异。结果共检出rs234681098、rs234681543、rs234681426和rs2346816454个UGT1A9的基因突变位点,30例患者达格列净稳态平均血药浓度为(10.62±6.18)ng/mL,不同基因型患者的达格列净血药浓度差异无统计学意义(P>0.05)。结论UGT1A9的rs234681098、rs234681543、rs234681426和rs234681645位点基因突变不影响2型糖尿病患者达格列净的血药浓度。Objective To investigate the correlation of dapagliflozin plasma concentration with the polymorphisms of uridine diphosphate-glucuronosyltransferase(UGT)1A9 gene in patients with type 2 diabetes mellitus(T2DM).Methods A total of 30 patients with T2DM treated with dapagliflozin in the hospital from March to June 2021 were selected.After at least 3 d of medication,the steady-state dapagliflozin plasma concentration was determined by the liquid chromatography-tandem mass spectrometry,the UGT1A9 genotype was sequenced by the sequencing method,and the differences in dapagliflozin plasma concentration among patients with different genotypes were compared.Results Four UGT1A9 gene mutation sites including rs234681098,rs234681543,rs234681426 and rs234681645 were detected.The average steady-state dapagliflozin plasma concentration in 30 patients was(10.62±6.18)ng/mL;there was no significant difference in the dapagliflozin plasma concentration among patients with different genotypes(P>0.05).Conclusion Mutations at rs234681098,rs234681543,rs234681426 and rs234681645 in UGT1A9 do not affect the dapagliflozin plasma concentration in patients with T2DM.

关 键 词：达格列净 UGT1A9 基因多态性 血药浓度 2型糖尿病 

分 类 号：R966[医药卫生—药理学]